BioSpecifics Technologies Corp. (BSTC) has reported a 6.36 percent rise in profit for the quarter ended Sep. 30, 2016. The company has earned $3.05 million, or $0.42 a share in the quarter, compared with $2.87 million, or $0.39 a share for the same period last year. Revenue during the quarter grew 9.42 percent to $6.88 million from $6.29 million in the previous year period. Total expenses were 31.33 percent of quarterly revenues, up from 31.29 percent for the same period last year. That has resulted in a contraction of 4 basis points in operating margin to 68.67 percent.
Operating income for the quarter was $4.73 million, compared with $4.32 million in the previous year period.
"BioSpecifics concentrates on developing XIAFLEX for medically necessary indications, and we look forward to the initiation of our Phase 1 clinical trial for the treatment of uterine fibroids by the end of this year," said Thomas L. Wegman, president of BioSpecifics. "Our partner Endo continues to see XIAFLEX as a core U.S. branded product and growth driver going forward. Cellulite is their main focus for non-marketed indications and they plan to announce Phase 2b data upon the completion of that trial. Endo is conducting a full commercial assessment and analysis of the R&D pipeline which will determine the clinical trial timelines moving forward."
Disclaimer: Please note that this is an auto-generated article. IRIS does not guarantee the accuracy, adequacy or completeness of any information and is not responsible for any errors or omissions or for the results obtained from the use of such information. IRIS especially states that it has no financial liability whatsoever to any user on account of the use of information provided on its website. For queries contact: [email protected]
